Valuation : Cytomedix, Inc.

Market Cap 60.54M 52.16M 49.39M 44.77M 83.99M 5.78B 84.41M 587M 226M 2.94B 227M 222M 9.3B P/E 2024
-27.4x
P/E 2025 -37.1x
Enterprise Value 60.59M 52.2M 49.43M 44.8M 84.06M 5.79B 84.48M 587M 226M 2.94B 228M 223M 9.31B EV / Sales 2024
47,922,901x
EV / Sales 2025 28,658,774x
Free-Float
42.11%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 63 2016-01-07
Chief Operating Officer 60 2014-03-29
Director TitleAgeSince
Director/Board Member 69 2009-01-29
Chairman 63 2012-02-06
Director/Board Member 67 2016-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.30%-2.95%+30.65%+247.47% 30.05B
Weighted average by Cap. -0.56%-2.83%+31.25%+170.65%

Financials

2024 2025
Net sales 1.37 1.18 1.11 1.01 1.89 130.42 1.9 13.23 5.09 66.35 5.13 5.01 209.67 3.31 2.85 2.7 2.45 4.6 316.56 4.62 32.11 12.35 161.05 12.44 12.17 508.9
Net income -2.32M -2M -1.9M -1.72M -3.22M -222M -3.24M -22.52M -8.66M -113M -8.73M -8.54M -357M -2.51M -2.16M -2.05M -1.86M -3.49M -240M -3.5M -24.34M -9.36M -122M -9.43M -9.23M -386M
Net Debt -120K -103K -97.5K -88.37K -166K -11.42M -167K -1.16M -445K -5.81M -449K -439K -18.35M 48.4K 41.7K 39.49K 35.79K 67.14K 4.62M 67.48K 469K 180K 2.35M 182K 178K 7.43M
Logo Cytomedix, Inc.
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!